A targeted new drug for a rare and aggressive form of lung cancer will be fast-tracked to eligible patients within weeks, thanks to a deal brokered by NHS England.

Patients in England will be the first in Europe to access Mobocertinib – the only precision drug available to patients with a mutation-driven, advanced form of lung cancer, who have already received chemotherapy.

Read more – NHSE & I (18/3/22)